Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada by Remington L. Nevin & Aricia M. Byrd
ORIGINAL RESEARCH
Neuropsychiatric Adverse Reactions to Mefloquine:
a Systematic Comparison of Prescribing and Patient
Safety Guidance in the US, UK, Ireland, Australia, New
Zealand, and Canada
Remington L. Nevin . Aricia M. Byrd
Received: April 19, 2016 / Published online: May 30, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: The antimalarial drug
mefloquine (MQ) is associated with
neuropsychiatric adverse reactions, some of
which may predict the development of more
serious effects. Although prescribing guidance
in the United States drug label (DL)
recommends to discontinue MQ at the onset
of neuropsychiatric symptoms, only certain
reactions are listed in both the DL and the
corresponding patient medication guide with a
recommendation to discontinue or to consult a
physician should they occur. To identify
possible prodromal reactions for which there is
complete or partial agreement in prescribing
and patient recommendations, a systematic
comparison of international drug safety
labeling was performed.
Methods: The full text of each DL and
medication guide (or equivalent) from six
primarily English-speaking countries was
reviewed to identify specific reactions with
corresponding recommendations in drug
safety labeling. Percentage agreement across
the countries in corresponding
recommendations was determined by
MedDRA high level group term (HLGT).
Results: Recommendations were found for
reactions in 22 neuropsychiatric HLGTs.
Complete or partial international agreement
was found for reactions in 11 (50%) HLGTs.
Conclusion: This analysis suggests
opportunities for physicians to improve
patient counseling and for international drug
regulators to clarify language in MQ safety
labeling to reflect national risk–benefit
considerations.
Keywords: Medication guide; Mefloquine;
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INTRODUCTION
Mefloquine (MQ) is a synthetic
quinoline-derivative antimalarial drug
structurally related to quinine that exhibits
idiosyncratic central nervous system toxicity
[1]. In double blinded studies, a range of
neuropsychiatric adverse reactions—including
strange or vivid dreams, dizziness, vertigo,
concentration impairment, anxiety, and
depression—are reported by 29–77% of MQ
users at prophylactic doses of 250 mg weekly
[2, 3]. Neuropsychiatric adverse reactions may
occur early during use—frequently within the
first three doses—and may even occur after only
a single dose [4, 5].
As evidenced by a recent retrospective cohort
study, among those reporting adverse reactions
to MQ, 21% of those reporting nightmares and
33% of those reporting cognitive dysfunction
identified these adverse reactions as persisting
over 3 years after use [6]. A boxed warning
added to the United States (US) drug label (DL)
in 2013 emphasizes that MQ may cause
‘‘neuropsychiatric adverse reactions that can
persist after mefloquine has been
discontinued’’. Prescribing guidance in the US
DL now recommends to discontinue (DC) MQ
at the onset of neuropsychiatric symptoms, as
certain of these may suggest an individual risk
of ‘‘more serious psychiatric disturbances or
neurologic adverse reactions’’ that could occur
with continued use of the drug. The US DL now
cautions that psychiatric reactions ‘‘ranging
from anxiety, paranoia, and depression to
hallucinations and psychotic behavior can
occur with mefloquine use’’ and ‘‘have been
reported to continue for months or years after
mefloquine has been stopped’’. The US DL now
also cautions that certain neurological reactions
‘‘have been reported to be permanent in some
cases’’ [7].
The highly prescriptive safety guidance in
the current DL reflects its gradual evolution
over the prior quarter century. At the time of
the US licensing of MQ in 1989, the original DL
instructed physicians only that, ‘‘[d]uring
prophylactic use, if signs of unexplained
anxiety, depression, restlessness or confusion
are noticed, these may be considered prodromal
to a more serious event. In these cases, the drug
must be discontinued’’ [8]. This language was
subtly updated in 2002, changing the
previously exclusive list of prodromal reactions
to an illustrative list by stating, ‘‘if psychiatric
symptoms such as [emphasis added] acute
anxiety, depression, restlessness or confusion
occur, these may be considered prodromal to a
more serious event. In these cases, the drug
must be discontinued and an alternative
medication should be substituted’’ [9].
The 2002 DL update introduced potential
ambiguity as to whether US physicians were to
counsel patients that the onset of any
psychiatric symptom should be considered
prodromal and prompt DC, or merely that
those explicitly listed and similar reactions
should be considered prodromal and prompt
DC. The 2013 DL update likewise noted,
‘‘[d]uring prophylactic use, the occurrence of
psychiatric symptoms such as acute anxiety,
depression, restlessness or confusion suggest a
risk for more serious psychiatric disturbances or
neurologic adverse reactions [emphasis added]. In
these cases, the drug should be discontinued
and an alternative medication should be
substituted’’. The 2013 boxed warning
addressed any remaining potential ambiguity
in this illustrative list by emphasizing simply,
‘‘During prophylactic use, if psychiatric or
neurologic symptoms occur, the drug should
be discontinued and an alternative medication
should be substituted’’ [7].
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The reasoning that prompted these changes
was not made explicitly clear in the 2013 DL or
in the accompanying US Food and Drug
Administration (FDA) drug safety
communication [10]. However, the following
year in a 2014 pharmacovigilance review, the
European Medicines Agency (EMA) concluded
‘‘a causal relationship between mefloquine and
the occurrence of long lasting and even
persistent neuropsychiatric effects’’, and noted
a ‘‘strong suspicion’’ that MQ could in some
cases cause ‘‘permanent brain damage’’ [11]. The
EMA noted that no ‘‘specific risk factors’’ could
be identified for these effects, and concluded,
‘‘[f]or that reason, only the advice—to stop
taking mefloquine if neuropsychiatric
reactions or changes to their mental state
occur—can be given as a precautionary
measure’’ [11].
In the US, in the case of certain drugs ‘‘that
pose a serious and significant public health
concern’’, the FDA may require specific safety
guidance be communicated directly to patients
in the form of a medication guide (MG)
provided at the time of dispensing, which
complements counseling received by the
patient at the time of prescribing [12]. The
FDA requires a MG when it determines patient
adherence to directions for use are considered
crucial to a drug’s effectiveness; when the drug
has serious risks relative to benefits; or when
patient safety guidance in the MG could help
prevent ‘‘serious adverse effects’’ [12].
Consistent with this final rationale, the MG
for MQ was first required by the FDA in 2003
[13].
The current US MG explicitly lists certain
psychiatric or neurologic adverse reactions for
which patients are recommended to consult
with a physician or healthcare provider (CP)
prior to taking their next dose. Although the US
boxed warning clearly recommends DC ‘‘if
psychiatric or neurologic symptoms occur’’, as
is the case with the MG, only certain specific
neurologic or psychiatric adverse reactions are
explicitly listed in the current US DL with a
recommendation to DC [7].
The rationale for the specific choice of listed
adverse reactions for which the US MG and DL
are in correspondence in recommending DC or
CP is not clear. The choice may reflect
consensus decision making between the FDA
and the drug’s manufacturers on those
prodromal or precursor adverse reactions that
most ‘‘suggest a risk for more serious psychiatric
disturbances or neurologic adverse reactions’’,
and which should, therefore, be specifically
highlighted in light of risk–benefit
considerations particular to the US regulatory
and legal environment. Such decision making
may include a consideration of the predictive
value of a particular prodromal or precursor
adverse reaction in foretelling more serious
reactions with continued use of the drug.
In other countries, based on the results of
independent regulatory decision making and
potentially differing risk–benefit considerations,
the particular choice of listed neurologic and
psychiatric adverse reactions for which DC or
CP may be recommended may differ from those
of the US. International agreement in specific
listed neurologic and psychiatric adverse
reactions for which MQ safety guidance
recommends DC or CP may, therefore, reflect
agreement on the strength of the evidence and
the consistency of risk–benefit decision making
motivating those recommendations.
To compare and contrast current
international recommendations for actions to
be taken in response to specific MQ neurologic
and psychiatric adverse reactions, and to identify
those categories of adverse reaction for which
there is international agreement in listing such
recommendations, a systematic comparison was
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performed of current prescribing and patient
safety guidance in the US and five other
primarily English-speaking countries: the
United Kingdom (UK), Ireland (IRL), Australia
(AUS), New Zealand (NZ), and Canada (CAN).
METHODS
Prescribing and Patient Safety Documents
Prescribing safety guidance in the UK and IRL is
provided in a document referred to as a
Summary of Product Characteristics; in AUS as
a product information; in NZ as a Data Sheet;
and in CAN as a product monograph—all of
which are herein referred to as a DL. Although
not always comparably mandated in each
country, patient safety guidance similar to that
provided in the US MG is provided in AUS and
NZ in a document referred to as the Consumer
Medicine Information; in IRL as the Patient
Leaflet; in the UK as the package leaflet; and in
CAN as information for the patient—all of
which are herein referred to as a MG.
The most recent MQ DL and MG as of
December 2015 were identified through a
search of the websites of national drug
regulators and drug manufacturers in each of
the six countries. The DL and MG were retrieved
for the innovator product (marketed as
Lariam, Roche Products Ltd.) in those
countries where the innovator product
remained marketed; and for the generic
product in those countries where the
innovator product had been withdrawn.
Review of Prescribing and Patient
Guidance
The full text of each DL and MG was then
reviewed by two clinicians to identify
recommendations for actions to be taken in
response to specific listed neurologic or
psychiatric adverse reactions. Disagreements
between the clinicians during review were
resolved by consensus.
Where a recommendation stated the drug
‘‘should’’ or ‘‘must’’ be discontinued or stopped
at the onset of a listed adverse reaction, this was
categorized as a recommendation to DC. Where
the text did not include an explicit direction to
DC or where the text suggested only that it
‘‘may be necessary to stop’’, but included a
recommendation to ‘‘consult immediately’’ or
‘‘consult’’ a healthcare provider at the onset of a
listed adverse reaction, this was categorized as a
recommendation to CP. Where contradictory
guidance for a listed adverse reaction appeared
in different locations in the text, a
recommendation to DC took precedence.
Where one or more adverse reactions were
listed ambiguously within a paragraph that
contained a particular recommendation
associated with a smaller list of adverse
reactions or a more general description of an
adverse reaction, the recommendation was
deemed to apply to that term. For example,
based on the following paragraph in the US DL,
a recommendation to DC was deemed to apply
to the adverse reactions dizziness, vertigo,
tinnitus, and loss of balance.
‘‘Neurologic symptoms such as dizziness or
vertigo, tinnitus, and loss of balance have
been reported. These adverse reactions may
occur early in the course of mefloquine use
and in some cases have been reported to
continue for months or years after
mefloquine has been stopped. Dizziness
or vertigo, tinnitus, and loss of balance
have been reported to be permanent in
some cases. During prophylactic use, if
neurologic symptoms occur, the drug
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should be discontinued and an alternative
medication should be substituted’’ [7].
Where the text referred explicitly to an
adverse reaction occurring only in the context
of a pre-existing condition or contraindication,
this was not included in this analysis. Similarly,
if an adverse reaction was described only in a
section of the text describing guidance
applicable prior to starting MQ, without
referencing explicitly that the adverse reaction
could also be caused by MQ, it was not included
in this analysis. Likewise, if an adverse reaction
appeared only in a table, without an explicit
inclusive reference in the text to a specific
recommendation, it was also not included in
this analysis.
Adverse reactions were considered as
neurologic or psychiatric according to the
Medical Dictionary for Regulatory Activities
(MedDRA, version 18.1) [14] if the MedDRA
lowest level term (LLT) matching the adverse
reaction was primarily or secondarily
categorized within either the MedDRA nervous
system or psychiatric disorders system organ
class (SOC). For example, the LLT dizziness,
categorized multiaxially within the MedDRA
under the SOCs cardiac disorders, vascular
disorders, and nervous system disorders, was
considered neurologic for the purposes of this
analysis. Where a listed LLT could be considered
both psychiatric and neurologic, it was
considered psychiatric. For example, the LLT
insomnia, categorized multiaxially within the
MedDRA under the SOCs psychiatric disorders
and nervous system disorders, was considered
psychiatric. Where a particular adverse
reaction—such as when expressed in consumer
language—did not explicitly match an LLT, the
closest relevant lexical or conceptual variant to
MedDRA terminology was substituted. For
example, the MedDRA LLT ‘‘masked facies’’
was substituted for the adverse reaction
‘‘difficulties with facial expression’’. Similarly,
the MedDRA LLT ‘‘restless’’ was substituted for
the adverse reaction ‘‘feeling restless’’. As similar
or equivalent adverse reactions may be reported
by a range of terminology, all LLTs were
grouped according to their MedDRA preferred
term (PT). For example, ‘‘restlessness’’ and
‘‘feeling restless’’ were grouped together on the
basis of their common PT ‘‘restlessness’’.
International Agreement
in Corresponding Prescribing and Patient
Guidance
Adverse reactions were organized according to
their MedDRA highest level grouping term
(HLGT). Those countries, whose MG and DL
both included a recommendation either to DC
or CP at the onset of a PT, were deemed to be in
correspondence for that adverse reaction.
Countries in correspondence for one or more
PT within each HLGT were identified, and for
each HLGT, the percentage agreement across all
six countries of the corresponding DL and MG
recommendations to DC or CP for one or more
PT was determined. HLGTs for which
corresponding MG and DL recommendations
to DC or CP for one or more PT were in
agreement for all six countries were deemed to
be in complete international agreement. HLGTs
for which corresponding MG and DL
recommendations to DC or CP for one or
more PT were in agreement for two or more
countries were deemed to be in partial
international agreement.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
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human or animal subjects performed by any of
the authors.
RESULTS
Atthe timeofanalysis, thedrug remained licensed
in all six countries, although the innovator
product had been withdrawn from the US as of
2011 and from CAN as of 2013 [15, 16]. Themost
recent generic US DL andMG available were each
dated June2013, and themost recentgenericCAN
DL and MG available were each dated March
2011. Lariam-branded DL and MG were available
for the UK, IRL, AUS, and NZ. The UK DL was
dated December 2015, and the MG was dated
April 2015. The IRL DL was dated June 2015, and
theMGwas datedMay2015. TheAUSDLandMG
werebothdatedNovember 2014,while theNZDL
and MG were both dated August 2014.
In addition to being explicitly recommended
by the US DL, the DLs of the UK and IRL also
explicitly recommended DC at the onset of
general neurologic or psychiatric symptoms.
Echoing the language in the earlier EMA
document [11], theUKand IRLDLrecommended:
‘‘If neuropsychiatric reactions or changes to the
mental state occur during mefloquine
chemoprophylaxis [emphasis added], the
patient should be advised to stop taking
mefloquine and seek medical advice
immediately, so that mefloquine can be
replaced by alternative malaria prevention
medication’’.
Among the six DLs and six MGs, additional
patient and prescribing guidance was identified
for specific adverse reactions within 22 distinct
neuropsychiatric HLGTs, comprising 14
psychiatric HLGTs (Table 1) and 8 neurologic
HLGTs (Table 2). There was complete agreement
across all six countries in correspondingMG and
DL recommendations to DC or CP for adverse
reactions within four (18%) of the HLGTs. These
HLGTs were anxiety disorders and symptoms,
changes in physical activity, depressed mood
disorders and disturbances, and deliria
(including confusion). There was partial
agreement across three of the six countries (US,
UK, and IRL) in corresponding MG and DL
recommendations to DC or CP for adverse
reactions within three (14%) additional HLGTs.
These HLGTs were disturbances in thinking and
perception, personality disorders and
disturbances in behavior, and suicidal and
self-injurious behaviors not elsewhere classified
(NEC). There was also partial agreement across
two of the six countries (UK and IRL) in
corresponding MG and DL recommendations
to DC or CP for adverse reactions within four
(18%) additional HLGTs. These were
neuromuscular disorders, schizophrenia, and
other psychotic disorders, sleep disorders and
disturbances, and peripheral neuropathies.
In a single country (US), there was also
corresponding MG and DL guidance to DC or
CP for adverse reactions within two (9%)
additional HLGTs. These were cranial nerve
disorders (excluding neoplasms) and
neurological disorders NEC. Among adverse
reactions within nine (41%) additional HLGTs,
although patient guidance in the MG from at
least two countries each recommended CP,
there was no corresponding guidance provided
to physicians for these specific adverse reactions
in the DL (Table 3).
DISCUSSION
Agreement in Prescribing and Patient
Guidance
This analysis finds complete international
agreement across the six countries in
corresponding prescribing and patient safety
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Table 1 Psychiatric adverse reactions to meﬂoquine, prescribing and patient guidance, by country
Adverse reaction HLGT (bold) and LLT US UK IRE AUS NZ CAN
DL MG DL MG DL MG DL MG DL MG DL MG
Anxiety disorders and symptoms
Agitation DC DC CP CP
(Acute/severe) anxiety/anxiety disorders/feeling
anxious
DC CP DC DC DC DC DC CP DC CP DC CP
Excitement CP CP
Nervousness/feeling nervous CP CP
Panic attack DC DC CP CP
Changes in physical activity
Restlessness/feeling restless DC CP DC DC DC DC DC CP DC CP DC CP
Cognitive and attention disorders and
disturbances
Disturbance with attention DC DC
Deliria (including confusion)
Confusion/feeling confused DC CP DC DC DC DC DC CP DC CP DC CP
Dementia and amnestic conditions
Forgetfulness CP CP
Depressed mood disorders and disturbances
Depression DC CP DC DC DC DC DC CP DC CP DC CP
Disturbances in thinking and perception
Hallucinations DC CP DC DC DC DC CP CP
Irrational ideasa CP CP
Strange or disturbing thoughtsb CP
Mood disorder and disturbances NEC
Irritability CP
Unusual changes in mood/change in mood/
strange moodc
DC DC CP CP
Psychiatric and behavioral symptoms NEC
Unusual behaviord CP DC DC
Personality disorders and disturbances in
behavior
Aggression DC DC CP CP
Feeling of mistrust towards others/paranoia DC CP DC DC DC DC
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guidance to CP or DC MQ in response to
specific psychiatric adverse reactions within
four HLGTs. These include the common
adverse reactions of depression and anxiety
within the HLGTs depressed mood disorders
and disturbances, and anxiety disorders and
symptoms. The DLs of the UK, IRL, AUS, and NZ
each describe anxiety and depression occurring
in C1/100–1/10 of prophylactic users.
In contrast, this analysis finds only partial
international agreement across two or more
countries in corresponding prescribing and
patient safety guidance to CP or DC in
response to specific neurologic and psychiatric
adverse reactions within an additional seven
HLGTs. These include the very common adverse
reaction of abnormal dreams, included within
the HLGT sleep disorders and disturbances. The
Table 1 continued
Adverse reaction HLGT (bold) and LLT US UK IRE AUS NZ CAN
DL MG DL MG DL MG DL MG DL MG DL MG
Psychiatric disorders NEC
Changes to the mental statee DC DC
Schizophrenia and other psychotic disorders
Losing touch with reality/psychosis DC DC DC DC
Psychotic behavior DC
Sleep disorders and disturbances
Abnormal dreams/strange dreams DC DC DC DC CP CP
Insomnia/(unable to/inability to) sleep/
difﬁculty sleeping
CP CP CP CP CP
Nightmares/bad dreams DC DC DC DC
Sleeping problemsf CP CP
Suicidal and self-injurious behaviors NEC
Attempted suicide DC DC DC DC
Suicidal thoughts/suicidal ideation/think about
suicideg
DC CP DC DC DC DC CP CP
Self-endangering behaviorh DC DC DC DC
AUS Australia, CAN Canada, CP consult physician, DC discontinue drug, DL drug label (or national equivalent), HLGT
MedDRA high level group term, IRL Ireland, LLT MedDRA lowest level term, MG medication guide (or national
equivalent), NEC not elsewhere classiﬁed, NZ New Zealand, UK United Kingdom, US United States
a LLT thinking irrational
b LLT thinking abnormal
c LLT mood change
d LLT abnormal behavior
e LLT mental state abnormal
f LLT sleep disorder
g LLT suicidal ideation
h LLT self-injurious behavior
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Table 2 Neurologic adverse reactions to meﬂoquine, prescribing and patient guidance, by country
Adverse reaction HLGT (bold) and LLT US UK IRE AUS NZ CAN
DL MG DL MG DL MG DL MG DL MG DL MG
Cranial nerve disorders (excluding neoplasms)
Difﬁculties with sense of smell or tastea CP CP
Changes to hearing/difﬁculties hearing/hearing
disturbancesb
CP CP CP
Things seem to sound too loudc CP CP
Ringing in ears/tinnitus DC CP CP CP
Headaches
Headache CP CP CP CP
Movement disorders (including parkinsonism)
Shaking/tremors CP CP CP CP
Difﬁculties with facial expressiond CP CP
Difﬁculties with head turninge CP CP
Clumsiness CP CP
Neurological disorders of the eye
Blurred vision CP CP CP CP
Neurological disorders NEC
Burningf DC DC
Difﬁculties talkingg CP CP
Difﬁculties with balance/loss of balanceh DC CP CP CP CP CP
Difﬁculties with eye movementi CP CP
Difﬁculties with facial sensationj CP CP
Difﬁculties with tongue movementk CP CP
Dizziness/light-headedness DC CP CP CP CP CP
Fainting/loss of consciousness CP CP CP CP
Numbness/numbness in the hands or feet/
tingling
DC DC CP CP
Painl DC DC
Pins and needles CP CP
Unsteadiness CP CP
Vertigo DC CP CP CP
Neuromuscular disorders
Weaknessm CP DC CP DC CP CP CP
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DLs of the UK, IRL, AUS, and NZ each describe
abnormal dreams occurring in C1/10 of
prophylactic users. Intriguingly, this analysis
finds a recommendation to DC at the onset of
reactions within the HLGT sleep disorders and
disturbances only in the DLs and MGs of the UK
and IRL. In contrast, the MG in CAN provides
no recommendation for such reactions and
notes only that certain of these usually ‘‘do
not cause people to stop taking the medicine’’.
In further contrast, the MGs of three other
countries—the US, AUS, and NZ—explicitly
recommend only CP for such reactions.
Unusually, the NZ MG lists abnormal or
strange dreams as serious side effects requiring
immediate CP. However, in contradiction to the
DL, which lists abnormal dreams as very
common, the MG states that such serious side
effects are rare.
For those other adverse reactions among the
remaining six HLGTs for which there is also
partial international agreement in
corresponding prescribing and patient safety
guidance, the DLs of the UK, IRL, AUS, and NZ
each list their incidence as unknown, or do not
specifically list the adverse reactions. In
contrast, for the adverse reactions vertigo and
dizziness, which are listed among the remaining
two HLGTs cranial nerve disorders, and
neurological disorders NEC, respectively, there
is corresponding prescribing and patient safety
guidance only in the DL and MG of a single
country (US). The DLs of the UK, IRL, AUS, and
NZ each describe vertigo and dizziness as
Table 2 continued
Adverse reaction HLGT (bold) and LLT US UK IRE AUS NZ CAN
DL MG DL MG DL MG DL MG DL MG DL MG
Peripheral neuropathies
Difﬁculties raising shouldersn CP CP
Neuropathy DC CP DC CP
Seizures (including subtypes)
Convulsions/seizures (ﬁt) CP CP
AUS Australia, CAN Canada, CP consult physician, DC discontinue drug, DL drug label (or national equivalent), HLGT
MedDRA high level group term, IRL Ireland, LLT MedDRA lowest level term, MG medication guide (or national
equivalent), NEC not elsewhere classiﬁed, NZ New Zealand, UK United Kingdom, US United States
a LLT disturbances of smell and taste
b LLT sensorineural hearing loss
c LLT hyperacusis
d LLT masked facies
e LLT cervical dystonia
f LLT burning sensation
g LLT dysarthria
h LLT balance difﬁculty
i LLT eye movement disorder
j LLT numbness in face
k LLT tongue movement disturbance
l LLT neurogenic pain
m LLT muscle weakness
n LLT neuralgic amyotrophy
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common, occurring in C1/100–1/10 of
prophylactic users.
Relevance of Findings
Demand for MQ has been negatively impacted
due to increased awareness of the drug’s
potential to cause lasting central nervous
system toxicity [1]—an outcome which,
despite numerous proposed pathophysiological
mechanisms [17–20], remains poorly
understood. Amidst losses in market share to
safer and better tolerated antimalarial drugs, the
innovator, Roche, has elected to withdraw
Table 3 Country-speciﬁc meﬂoquine patient and prescribing guidance, number recommending DC or CP for one or more
adverse reactions, and number and countries with corresponding guidance for both, by adverse reaction HLGT
Adverse reaction HLGT MG DL Corresponding MG and DL guidance
n n n (%) Countries
Anxiety disorders and symptoms 6 6 6 (100) US, UK, IRL, AUS, NZ, CAN
Changes in physical activity 6 6 6 (100) US, UK, IRL, AUS, NZ, CAN
Depressed mood disorders and disturbances 6 6 6 (100) US, UK, IRL, AUS, NZ, CAN
Deliria (including confusion) 6 6 6 (100) US, UK, IRL, AUS, NZ, CAN
Disturbances in thinking and perception 5 3 3 (50) US, UK, IRL
Personality disorders and disturbances in behavior 5 3 3 (50) US, UK, IRL
Suicidal and self-injurious behaviors NEC 5 3 3 (50) US, UK, IRL
Neuromuscular disorders 5 2 2 (33) UK, IRL
Schizophrenia and other psychotic disorders 2 3 2 (33) UK, IRL
Sleep disorders and disturbances 5 2 2 (33) UK, IRL
Peripheral neuropathies 2 2 2 (33) UK, IRL
Cranial nerve disorders (excluding neoplasms) 5 1 1 (17) US
Neurological disorders NEC 5 1 1 (17) US
Mood disorder and disturbances NEC 5 0 0 (0)
Headaches 4 0 0 (0)
Movement disorders (including parkinsonism) 4 0 0 (0)
Neurological disorders of the eye 4 0 0 (0)
Psychiatric and behavioral symptoms NEC 3 0 0 (0)
Cognitive and attention disorders and disturbances 2 0 0 (0)
Dementia and amnestic conditions 2 0 0 (0)
Psychiatric disorders NEC 2 0 0 (0)
Seizures (including subtypes) 2 0 0 (0)
AUS Australia, CAN Canada, CP consult physician, DC discontinue drug, DL drug label (or national equivalent), HLGT
MedDRA high level group term, IRL Ireland, MG medication guide (or national equivalent), NEC not elsewhere
classiﬁed, NZ New Zealand, UK United Kingdom, US United States
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Lariam-branded MQ from a number of
additional countries besides the US and CAN;
to include IRL, Germany, and Denmark [21].
Although there are concerns the drug may soon
be withdrawn from other countries for similar
reasons [22], MQ is likely to remain available
internationally in generic forms for some time.
This analysis provides important insights that
may be relevant during patient counseling and
in the consideration of potential future
improvements to MQ safety guidance.
For example, as MQ prophylaxis is
commonly prescribed for travelers, who by
definition may be far from the prescribing
physician or healthcare provider at the time
that adverse reactions occur, CP may not be
immediately feasible, delaying any potential
recommendation to DC in the case of a
particular psychiatric or neurologic adverse
reaction for which the MG recommends only
CP. Similarly, even in the event that CP is
immediately available—such as by telephone or
email—lack of explicit recommendation in an
MG for a patient to seek CP for a particular
adverse reaction may also delay any potential
physician direction to DC should the patient
not recognize its significance. A review of
narrative reports of MQ adverse reactions may
aid national drug regulators in determining
whether the failed recognition of the
significance of a particular adverse reaction
identified in this analysis, or delays in CP
related to travel, may have contributed to
more serious events. Such a review may also
aid regulators in determining whether such
more serious events may have been potentially
preventable through the inclusion of more
explicit recommendations to CP or DC the
drug at the onset of particular prodromal
reactions—such as sleep disorders and
disturbances—for which there is already partial
international agreement in prescribing and
patient safety guidance.
Current national guidelines for the use of
MQ in malaria prophylaxis among travelers
may be informed by current safety guidance in
the national DL and MG. Differences in
prescribing and patient safety guidance
between countries may inform differential
national recommendations for use of MQ, and
contribute to disagreement in the setting of
common international guidelines. This analysis
may aid as a starting point for developing
consensus for international guidelines on the
use of MQ in spite of significant international
disagreement in the current safety guidance.
Similarly, disagreement in international
prescribing and patient safety guidance may
contribute to apparently contradictory
situations, where similar patients from similar
countries, who experience identical neurologic
or psychiatric adverse reactions from MQ while
traveling, are directed to take discordant actions
in response. For example, under current
guidance in country-specific MGs, travelers
from the UK and IRL are directed to DC MQ at
the onset of abnormal dreams, while travelers
from AUS and NZ are directed merely to CP and
not to DC at their onset. In contrast, travelers
from the US are provided with no specific advice
for actions to be taken at the onset of this very
common adverse reaction, while travelers from
CAN are advised that bad dreams are ‘‘usually
mild’’ and ‘‘do not cause people to stop taking
the medicine’’. Such discordance, while
presumably reflecting markedly differing
national risk–benefit decision making, may
contribute to confusion among travelers and
to country-specific guidance not being
followed. This analysis is expected to aid in
clearly identifying those classes of neurologic
and psychiatric adverse reactions for which
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there is disagreement in international
recommendations, permitting physicians and
healthcare providers to appropriately
emphasize national guidance.
Limitations
This analysis has a number of limitations.
Significantly, this analysis is limited to a
review of prescribing and patient safety
guidance from only six developed countries.
These countries were chosen based on their
principal use of English and a shared common
cultural and linguistic heritage. The measures of
international agreement in prescribing and
patient safety guidance from this analysis can,
therefore, not be generalized to other countries,
whose prescribing and patient guidance were
not specifically reviewed.
In addition, this analysis relies on a subjective
interpretation of the language in the various DLs
and MGs. Although reflecting consensus opinion
among the study authors, based on the imprecise
nature of this language, and the systematic but
arbitrary rules employed in this analysis, theremay
be reasonable disagreement by others as to
whether a DL or MG should be interpreted as
recommending DC or CP at the onset of a
particular adverse reaction. This limitation
reflects the disagreement that may be expected
between individual prescribers and patients in
interpreting recommendations in the DL andMG.
In certain cases, this analysis may also have
assigned certain adverse reactions to an HLGT
distinct from what might have been seemingly
implied by the patient or prescribing guidance.
For example, based on the use of the MedDRA to
categorize particular listed adverse reactions, this
analysis assigned many neurologic LLTs that
might be considered most consistent with
peripheral neuropathy—including pain and
numbness—to the HLGT neurological disorders
NEC. However, both the UK and the IRL DL
state, ‘‘[m]efloquine should be discontinued in
patients experiencing symptoms of neuropathy,
including pain, burning, tingling, numbness,
and/or weakness in order to prevent the
development of an irreversible condition
[emphasis added]’’. This limitation reflects the
fact that idiomatic language commonly used by
patients, physicians, and other healthcare
providers may not necessarily adhere to the
standard MedDRA vocabulary [23].
CONCLUSIONS
MQ prescribing guidance in a growing number
of countries now recommends DC at the onset
of any neuropsychiatric adverse reaction. This
analysis has identified certain common and
very common neuropsychiatric adverse
reactions to MQ for which DC is explicitly
recommended and for which there is complete
or partial international agreement these
reactions be specifically listed in both
prescribing and patient guidance.
The results of this analysis suggest
opportunities for physicians in these countries
to improve patient counseling by specifically
emphasizing the need to DC at the onset of these
adverse reactions. The results of this analysis also
suggest opportunities for international drug
regulators to clarify language in future updates
to remaining MQ DLs and MGs to better reflect
national risk–benefit considerations for
continued use of the drug.
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